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Abstract
Background: Chronic pain is a prevalent condition that causes functional impairment and emotional suffering. To
allay pain-induced suffering, opioids are often prescribed for chronic pain management. Yet, chronic pain patients
on opioid therapy are at heightened risk for opioid misuse—behaviors that can lead to addiction and overdose.
Relatedly, chronic pain patients are at elevated risk for suicidal ideation and suicidal behaviors.
Main body: Opioid misuse and suicidality are maladaptive processes aimed at alleviating the negative emotional
hyperreactivity, hedonic hyporeactivity, and emotion dysregulation experienced by chronic pain patients on opioid
therapy. In this review, we explore the role of emotion dysregulation in chronic pain. We then describe why
emotionally dysregulated chronic pain patients are vulnerable to opioid misuse and suicidality in response to these
negative affective states.
Conclusion: Emotion dysregulation is an important and malleable treatment target with the potential to reduce or
prevent opioid misuse and suicidality among opioid-treated chronic pain patients.
Keywords: Anhedonia, Chronic pain, Emotion dysregulation, Opioid misuse, Reinforcement, Suicidality
Background
Approximately 100 million Americans suffer from
chronic pain, a condition compounded by maladaptive
cognitive and emotional processes that often cooccur
with protracted and severe physical suffering [1]. Opioid
therapy continues to be the primary medical treatment
for chronic pain despite associated risks, including opi-
oid misuse, addiction, and overdose [2], as well as dele-
terious neuropsychopharmacologic effects of prolonged
opioid exposure, including dysregulation in brain circuits
undergirding reward processing, stress reactivity, and
the proactive regulation of emotions [3, 4]. Given the
magnitude of the current opioid crisis in the U.S., there
is an urgent need to understand the psychological fac-
tors that drive individuals with chronic pain to misuse
their prescribed opioid medications. Furthermore, the
clinical presentation of opioid-treated chronic pain
patients is often complicated by comorbid psychiatric
distress, substance use disorders, and suicidality [5–7]—
so-called “epidemics of despair” that account for rising
mortality rates in the U.S. [8]—in part through intentional
opioid overdose. Yet, biobehavioral mechanistic models
linking chronic pain to opioid misuse and suicidal be-
havior are lacking.
In this conceptual review, we posit that the transdiag-
nostic process of emotion dysregulation is central to un-
derstanding why opioid-treated chronic pain patients
engage in opioid misuse and suicidal behaviors. Al-
though emotion dysregulation may result in multiple
forms of maladaptive behavior, here we focus on opioid
misuse and suicidality as sequelae of chronic pain due to
their high prevalence and significant public health im-
pact. Recent meta-analyses suggest that 25% of chronic
pain patients engage in opioid-misusing behaviors like
opioid dose escalation or self-medicating negative
affective states with opioids [9]. As will be discussed
later, opioid misuse is associated with adverse conse-
quences such as increased sensitivity to pain and stress,
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decreased sensitivity to natural rewards, functional im-
pairments, and overdose risk [10–12]. Similarly, suicidal-
ity, which encompasses both suicidal ideation and
behaviors, is especially common among individuals with
chronic pain. Chronic pain patients have nearly two
times the risk of death by suicide and are two to three
times more likely than individuals without chronic pain
to report suicidal ideation or make suicide attempts [13].
Drug overdose is the most commonly reported means of
attempting suicide among chronic pain patients [14].
Given high rates of suicidal ideation and suicide at-
tempts among chronic pain patients, and the ready pres-
ence of lethal means via opioid prescription, risk of
death by suicide warrants particular attention among
opioid-treated chronic pain patients—a population
already at increased mortality risk [15, 16].
The primary aim of this review is to explore interrela-
tionships of emotion dysregulation and opioid-treated
chronic pain, and in particular, to propose how these
factors give rise to opioid misuse and suicidality. To
this end, we first describe emotion dysregulation
among opioid-treated chronic pain patients. We then
explore the role of emotion dysregulation as a trans-
diagnostic process underlying the development and
maintenance of opioid misuse and suicidality in this
high-risk population. Finally, we conclude by consider-
ing how psychological interventions designed to en-
hance affect regulation might address the emotion
dysregulatory processes subserving opioid misuse and
suicidality among chronic pain patients receiving long-term
opioid treatment.
Emotion, appraisal, and emotion dysregulation in
chronic pain
The cognitive-motivational-relational theory of emotion
asserts that emotions arise in response to a cognitive ap-
praisal of the meaning or significance of a particular
stimulus context [17]. In other words, the relational
meaning one derives through the process of appraisal in
response to a given situation determines whether one
experiences sadness, happiness, or some other emo-
tion. From this perspective, appraisals drive emotions
and thereby shape emotion regulatory attempts [17].
With respect to chronic pain, when patients experi-
ence an aggravation in the symptomatic expression of
their underlying painful condition or encounter an
emotionally-distressing situation, they may respond in
maladaptive ways depending on how they appraise the
situation. For example, appraisals of situational help-
lessness, hopelessness, or feelings of interpersonal
burdensomeness may drive opioid misuse as a coping
strategy or thoughts of suicide as a way to escape the
situation.
In this review, we posit that emotion dysregulation is
the process that links these situational appraisals to
maladaptive behaviors, including opioid misuse and sui-
cidality (see Fig. 1 for a depiction of this process). Emo-
tion dysregulation is marked by difficulties with the
emotion-generative process and/or emotion regulation
failures—i.e., not effectively employing adaptive emotion
regulation strategies when it would be appropriate to do
so [18]. The decreased hedonic capacity [19] and height-
ened stress sensitization [20] associated with chronic
pain and long-term opioid therapy indicate difficulties in
the emotion-generative process. Emotion-generation diffi-
culties may result in persistent negative affect that con-
tributes to emotion dysregulation [18], and thus, these
difficulties are relevant to the development and mainten-
ance of opioid misuse and suicidality. Relying on mal-
adaptive coping strategies to regulate negative cognitions
and affect (like misuse of opioids to self-medicate dys-
phoric emotional states or attempting suicide to escape
from emotional suffering) would be considered emotion
regulation failures. Additionally, reappraisal and sup-
pression, classic forms of emotion regulation, may go
awry in response to chronic pain [21]—a subject we will
address in our discussion of factors contributing to emo-
tion dysregulation among opioid-treated chronic pain
patients.
Difficulties with the emotion-generative process
In their review of the roles of emotion and emotion
regulation in psychopathology, Gross and Jazaieri (2014)
outlined areas where individuals might experience
emotion-related difficulties, e.g., emotion intensity and
emotion duration [18]. These difficulties with the
emotion-generative process are relevant to chronic pain
patients given the high levels of psychiatric comorbidi-
ties present in this population. Hyperreactivity or hypor-
eactivity, i.e., exhibiting too large or too small an
emotional response to a given situation, are indicative of
problematic emotional intensity [22]. Among chronic
pain patients, distressing situations may elicit negative
emotional hyperreactivity [20], whereas rewarding situa-
tions may result in blunted positive emotional re-
sponses—i.e., hedonic hyporeactivity [19]. Just as the
experience of pain may modulate emotional intensity
[23], pain may also affect the duration of emotional ex-
perience. As the experience of pain transitions from an
acute to a chronic condition, negative affective reactions
may become more common and long-lasting due to in-
creasingly catastrophic appraisals of pain [24].
In the context of recurrent negative emotionality and
hedonic hyporeactivity, individuals may become hyper-
vigilant for perturbations to their normative physio-
logical state and negatively appraise their bodily
condition as problematic. For chronic pain patients,
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momentary fluctuations in pain or other somatic states
may be misinterpreted as dangerous or an indication of
damage to the body rather than benign physiological
sensations that do not signal harm [25]. These negative
interpretations can lead to a cascade of negative emo-
tions or catastrophic thinking that interferes with indi-
viduals’ ability to regulate emotional distress. Given
evidence for interoceptive deficits among individuals
with chronic pain [26, 27], chronic pain patients may
struggle with differentiating pain sensations from the
autonomic, visceral, and musculoskeletal changes evoked
by negative emotions. The tendency to label pain as
“awful,” “horrible,” or with other emotionally-laden de-
scriptors suggests pain can become conflated with the
emotional distress it creates [28]. Because interoceptive
awareness facilitates emotion regulation [29], chronic
pain patients with interoceptive deficits may be less able
to discriminate pain from the physical sequelae of nega-
tive emotions, and therefore are less inclined (or able) to
engage in proactive emotion regulation attempts.
Factors contributing to emotion dysregulation
When chronic pain patients do attempt to regulate their
emotions, ineffective strategies or skills deficits may im-
pede their ability to experience emotional relief. For ex-
ample, in response to negative appraisals, suppression
may be employed in an attempt to regulate negative
emotional responses. However, suppression of unwanted
thoughts and emotions paradoxically leads to more in-
tense emotional reactions as cognitive resources become
exhausted [21]. Additionally, thought suppression is as-
sociated with greater pain severity, pain interference,
and depressive symptoms among chronic pain patients
with trauma histories [30], and increased opioid craving
among chronic pain patients with depressive symptoms
[31]. Rather than engaging in suppression, individuals
may attempt to regulate their emotions through re-
appraisal, a cognitive emotion regulation strategy fo-
cused on decreasing negative affect by reinterpreting
situations in more adaptive ways [32]. However, studies
suggest that both chronic pain and opioid use interfere
with reappraisal processes and decrease reappraisal effi-
cacy [33, 34]. From a neurobiological perspective, emo-
tion regulation failures may result from inefficient
top-down prefrontal modulation of bottom-up limbic
activation—a pattern of neural dysfunction that has been
observed among chronic pain patients [35]. When sup-
pression or reappraisal efforts fail, opioid-treated pain
patients may turn to problematic emotion regulation
strategies (i.e., opioid misuse or suicidal behavior) as
means of experiencing relief from their negative cogni-
tions and affect.
Emotion dysregulation as a transdiagnostic
process in chronic pain
Mental health professionals have traditionally relied on
categorical descriptions to classify psychiatric disorders,
Chronic pain Opioid use
Emotion 
dysregulation
Negative 
cognitions & affect
Opioid craving
Opioid misuse
Reinforcement
(decreased negative 
affect or increased 
positive affect)
Negative 
cognitions & affect
Suicidal ideation
Suicidal behaviors 
(e.g., preparatory 
behaviors)
Reinforcement
(decreased negative 
affect or increased 
positive affect)
Fig. 1 This model highlights the links between emotion dysregulation,
opioid misuse, and suicide risk among chronic pain patients as outlined
in this review. The recurrent experience of pain and long-term opioid
exposure may drive emotion dysregulation in the form of negative
emotional hyperreactivity and hedonic hyporeactivity, as well as deficits
in the ability to proactively regulate emotions. Chronic pain patients
prescribed long-term opioids who experience emotion dysregulation
may respond with risky or maladaptive behaviors through a process of
negative cognitions and affect. Specifically, as chronic pain patients
become caught up in negative thoughts and feelings about their pain
(e.g., pain catastrophizing), they may experience craving for opioids as a
way to relieve those negative thoughts and feelings or thoughts of
suicide as a way of escaping their present experiences. If they engage in
opioid-misusing behaviors and experience either relief from negative
affect or increased positive affect, they become more likely to engage in
those behaviors as ways to manage distress through a process of
reinforcement. Relatedly, suicidal behaviors, such as planning or
preparatory behaviors, may result in relief from negative affect or
increased positive affect when chronic pain patients feel like they
have the means to escape their pain and distress. For example,
hoarding medications, an indication of opioid misuse, can also be
considered a preparatory behavior given the primary method of
suicide planning endorsed by chronic pain patients is medication
overdose. These links likely represent recursive processes, e.g., just
as chronic pain and opioid use lead to emotion dysregulation, so
does emotion dysregulation likely contribute to increased pain and
opioid use. Similarly, although opioid misuse and suicidal behaviors may
be employed in response to emotion dysregulation, they ultimately may
lead to more frequent instances of emotion dysregulation
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in contrast to a newer transdiagnostic perspective that
eschews discrete taxonomies to consider underlying and
universal processes undergirding impaired functioning
[36]. A transdiagnostic approach may more effectively
characterize the maladaptive psychological conditions
that commonly cooccur with chronic pain [37, 38]. For
example, chronic pain patients are at increased risk for
comorbid psychiatric disorders, including depression,
trauma, and substance use disorders. Indeed, it has been
estimated that up to 85% of chronic pain patients experi-
ence severe depression [39, 40], between 10 and 50% re-
port a history of trauma [41], and 16% exhibit substance
use disorders above and beyond misuse of prescription
opioids [7]. Although these psychiatric comorbidities
have been traditionally studied as separate nosological
entities with distinct etiologies, emerging research sug-
gests that they share common transdiagnostic processes
that may explain their association with chronic pain.
Emotion dysregulation is one such transdiagnostic
process that subserves the development and mainten-
ance of disrupted functioning and maladaptive behaviors
across an array of physical and mental health conditions
[42, 43]. Emotion dysregulation may be antecedent and
consequent to chronic pain. For instance, individuals
with a trait-like propensity towards emotion dysregula-
tion may be at greater risk for developing chronic pain
following an acute injury. However, as pain progresses
from an acute to chronic condition, many individuals
develop an attentional bias to pain-related information
such that their attention becomes preferentially allocated
to sensations of pain and environmental stimuli associ-
ated with pain episodes [44, 45]. Over time, the experi-
ence of pain coupled with this attentional bias can result
in pain catastrophizing [46] and persistent negative cog-
nitions, e.g., “This pain will never end” or “This is the
worst pain I have ever felt.” When pain sensations are
interpreted through the lens of catastrophic cognitive
appraisals, chronic pain patients may experience dysreg-
ulated emotions, manifested by decreased distress toler-
ance [47] and heightened stress reactivity [20]. In turn,
the consequent deficits in positive affect and surfeits in
negative affect result in heightened pain sensitivity [48],
which thereby exacerbates and prolongs chronic pain.
The escalation over time of this downward spiral of pain
sensations, biased attention to pain cues, pain catastro-
phizing, and dysregulated emotions may drive chronic
pain patients to misuse opioids [4] or attempt suicide as
ways of responding to their overwhelming distress.
For the remainder of this review, we focus on opioid
misuse and suicidality—two maladaptive processes that
are especially prevalent and pernicious among individ-
uals with chronic pain. Chronic pain patients prescribed
opioid therapy may turn to opioid misuse and suicidality
in response to instances of emotion dysregulation,
especially in the absence of other available adaptive coping
strategies [9, 13]. Insofar as skill and self-efficacy are ne-
cessary for effective implementation of emotion regulation
strategies [18], psychotherapeutic interventions that pro-
vide affect regulation training may prevent opioid misuse
and suicidal behavior in the context of chronic pain. As
such, we conclude with a discussion of promising be-
havioral treatment approaches to remediate emotion
dysregulation among chronic pain patients [49, 50].
Maladaptive responses to emotion dysregulation
Opioid misuse among opioid-treated chronic pain
patients
Despite increasing recognition of the public health risks of
opioid analgesic pharmacotherapy [2], a dearth of access-
ible, alternative treatments has led to an over-reliance on
opioids and adverse consequences for chronic pain pa-
tients [51]. These consequences include misuse of medi-
cation (e.g., unauthorized dose escalation) as a way to
escape from pain, manage mood, and relieve stress—
behaviors that are maintained through a process of
negative reinforcement. Chronic pain is an ever-present,
aversive experience. Research supports that relief of on-
going pain increases dopamine transmission and negative
reinforcement of the behavior (e.g., [50, 51]). When a
chronic pain patient relieves pain with opioids, taking
medication is negatively reinforced [52, 53]. Over time,
some patients will begin to take their medication more
frequently or in higher doses to experience less pain or
greater relief for longer periods of time. Neuropharmaco-
logical studies demonstrate that opioids bind to
mu-opioid receptors in brain regions subserving pain per-
ception, emotional experience, and reward (i.e., pleasure
and well-being) [54]. Opioidergic activation of reward cir-
cuitry, including the ventral tegmental area and nucleus
accumbens, results in feelings of euphoria [55]. Conse-
quently, chronic pain patients begin to associate
opioid-related cues (e.g., the sight of a pill bottle) with that
euphoria [56], leading to an attentional bias toward opioid
cues [57] and the subjective experience of craving [58] ir-
respective of the need to obtain pain relief. This process of
conditioning may drive opioid dose escalation and result
in opioid use that increases risk of overdose [54].
Moreover, chronic opioid use and misuse may result
in allostatic changes to limbic and striatal brain circuitry
leading to a persistent and escalating hedonic deficit
characterized by increased sensitivity to stress and pain
coupled with decreased sensitization to natural rewards
[4, 59, 60]. As a result of this allostatic process,
opioid-misusing chronic pain patients evince blunted
autonomic responses during processing of natural re-
wards and while attempting to regulate negative emo-
tions through reappraisal [61]. Indeed, opioid-misusing
chronic pain patients report less use of reappraisal than
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pain patients who take opioids as prescribed, and these
deficits in reappraisal use predict heightened affective
distress and opioid craving (Garland EL, Hanley AW,
Bedford C, Zubieta JK, Howard MO, Nakamura Y,
Donaldson GW, Froeliger, B. Reappraisal deficits among
prescription opioid misusing chronic pain patients, sub-
mitted). This opioid-induced emotion dysregulation may
exacerbate pre-existing affective disorders that antedate
chronic pain and initiation of opioid analgesic use [62,
63]. Thus, individuals who are vulnerable to negative
affect may be more likely to misuse medication to offset
dysphoria, which may exacerbate negative mood via allo-
static neuroadaptations to brain circuits involved in emo-
tion regulation. Relatedly, through processes of positive
and negative reinforcement, individuals become more
likely to continue engaging in opioid misuse as an emo-
tion regulatory (i.e., coping) mechanism; the euphorigenic
neuropsychopharmacological effects of opioids may tem-
porarily increase positive affect and decrease negative
affect, propelling the cycle of escalating opioid misuse to-
ward opioid addiction [4].
Suicidality among opioid-treated chronic pain patients
Although the mechanisms linking suicidality to chronic
pain are still being explored, consistent evidence has
demonstrated that chronic pain patients are at height-
ened risk for experiencing suicidal thoughts and exhibit-
ing life-threatening behaviors [13, 64, 65]. The link
between chronic pain and suicidality may, in part, be ex-
plained by emotion dysregulation. For example, suicidal-
ity is often preceded by persistent negative affect and
anhedonia [66–69], two characteristics that often de-
velop in response to pain. Specifically, as individuals ex-
perience repeated instances of heightened negative affect
because of pain and stress (i.e., negative emotional hy-
perreactivity), they may experience a concomitant blunt-
ing of hedonic capacity—the ability to experience
pleasure from naturally rewarding objects and events in
the social environment [19]. This deficit in hedonic cap-
acity may be exacerbated by the neuropsychopharmacolo-
gic effects of chronic opioid use, as articulated above. In the
absence of healthy hedonic tone (i.e., hedonic hyporeac-
tivity), chronic pain patients may respond to distressing
situations with suicidal ideation, e.g., thoughts of escap-
ing the resultant negative cognitive-affective states. In
support of this, our team recently published a study on
the association between suicidal ideation and prescrip-
tion opioid craving and cue-reactivity [69]. Among a
sample of 115 chronic pain patients, we found that sui-
cidal ideation predicted opioid cue-reactivity, as mea-
sured by heart rate variability while completing a
dot-probe task, via self-medication urges. Just as opioid
misuse is strengthened through processes of negative
and positive reinforcement, chronic pain patients may
experience suicidality with increasing frequency and in-
tensity due to physical pain and emotional distress. Sui-
cidality is negatively reinforced insofar as suicidal ideation
and suicidal behaviors (e.g., preparatory behaviors) may
relieve negative cognitions and affect [70, 71]—in other
words, as individuals consider suicide as a way of es-
caping pain or hoard their opioids in preparation of
attempting suicide, they may experience relief from
thoughts of burdensomeness or feelings of hopelessness
now that they have determined a way to end their suf-
fering. These suicidal thoughts and behaviors may pro-
duce positive affect, such as feelings of calm or
acceptance of death. The dangerous escalation and
cooccurrence of opioid misuse and suicidality may re-
sult in death by overdose or suicide if left untreated.
Psychotherapeutic mechanisms addressing
emotion dysregulation
A growing body of literature has illustrated the effective-
ness of psychosocial interventions to address chronic
pain. For example, a recent systematic review of ran-
domized controlled trials (RCTs) of mindfulness-based
interventions (MBIs) for chronic pain demonstrated sig-
nificant improvements in pain, depression symptoms,
and quality of life [50]. Similarly, cognitive-behavior
therapy (CBT) has been extensively researched as a
treatment for chronic pain, and has demonstrated effi-
cacy for reducing pain-related interference by restructur-
ing the cognitive distortions that arise in response to
pain, as well as by increasing activity scheduling and
pacing [72]. Though both MBIs and CBT can reduce
negative emotional hyperreactivity [50, 72], neither
MBIs nor CBT are specifically focused on remediating
hedonic hyporeactivity undergirding opioid misuse and
suicidality among chronic pain patients—a key risk
mechanism thought to perpetuate the downward spiral
of behavioral escalation articulated above. In contrast,
Mindfulness-Oriented Recovery Enhancement (MORE)
is a novel intervention that combines principles of
mindfulness, CBT, and positive psychology to target he-
donic dysregulation in addiction, affective disorders,
and chronic pain through training in mindfulness, re-
appraisal, and savoring skills [73, 74]. Completed and
ongoing RCTs are demonstrating positive effects of this
intervention on treating pain symptoms and opioid
misuse among chronic pain patients prescribed opioid
therapy [75]. From a mechanistic perspective, the three
primary components of MORE may be especially effica-
cious means of remediating the emotion dysregulation
that impels both opioid misuse and suicidality among
chronic pain patients.
Mindfulness can be conceptualized as a practice, a
state, and a trait [76]. The state of mindfulness is char-
acterized by a nonreactive, metacognitive awareness and
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acceptance of present moment thoughts, emotions, and
sensations [77]. Mindfulness practices include mindful
breathing, body scan meditations, and the informal prac-
tice of mindfulness during everyday tasks and activities.
As one evokes the state of mindfulness through these
practices, one begins to develop the trait of mindfulness,
or dispositional mindfulness [78]. With respect to the
focus of this article, trait mindfulness is positively associ-
ated with psychological well-being [79] and negatively
associated with self-medication of negative emotions
with opioids among a sample of chronic pain patients
[80]. Mindfulness practice appears to strengthen the
function and structure of prefrontally-mediated cognitive
control networks [80–83], including those associated
with emotion regulation, which in turn promotes
top-down regulation of bottom-up emotional impulses
[83, 84]. Moreover, mindfulness alleviates pain by facili-
tating a shift from affective to sensory processing of pain
sensations [75, 85] and reducing thalamic amplification
of nociceptive input via prefrontal cognitive control
mechanisms [86, 87]. In these ways, mindfulness training
can promote emotion regulation, reduce pain, and pre-
vent maladaptive coping behaviors.
Reappraisal is an adaptive emotion regulation skill that
can interrupt intense or persistent negative emotions
[88]. Recent neuroscientific research demonstrates that
it may also activate brain reward circuitry in ways con-
sistent with positive emotion regulation [89]. Specifically,
as individuals examine irrational or unhelpful cognitions
that arise in response to distressing situations and
recognize how those perceptions influence their emo-
tional experiences, they can dispute those negative cog-
nitions through the process of reappraisal and thereby
experience consequent decreases in negative affect and
increases in positive affect. Further, cognitive regulation
strategies like reappraisal have been shown to be an es-
pecially potent means of decreasing pain intensity, in
part though cortical modulation of pain and concomi-
tant emotional reactivity [90, 91]. According to recent
theorizing, reappraisal may also be strengthened by
mindfulness practice [92]—a claim supported by empir-
ical evidence [93, 94]. MORE capitalizes on the synergy
of mindfulness and reappraisal to strengthen emotion
regulation capacity.
The final component of MORE, savoring, targets he-
donic hyporeactivity resulting from chronic pain and
long-term exposure to opioids [60]. Savoring is an emo-
tion regulation strategy in which the individual mindfully
attends to features (e.g., the sight, sound, scent, and feel)
of naturally-rewarding stimuli (e.g., beauty of the natural
world, affiliative rewards, pleasurable physical sensations)
while metacognitively monitoring and appreciating pleas-
ant emotions and higher-order affective meaning arising
from the encounter with the pleasant stimulus. According
to the restructuring reward hypothesis [74], savoring may
counter hedonic hyporeactivity underlying opioid misuse
by shifting valuation of drug-related rewards back to valu-
ation of natural rewards. A number of studies have pro-
vided support for the restructuring reward hypothesis by
demonstrating effects of MORE on autonomic [95, 96],
electrocortical [97], and neural functional [98] measures
of reward processing that were in turn correlated with re-
ductions in drug craving and use/misuse. Moreover, in-
creasing positive affect has analgesic effects [99], and in
that regard, increasing brain reward responses through
mindfulness and other behavioral manipulations has been
associated with decreased pain [100, 101].
MORE shares common transtherapeutic processes
with other MBIs and CBT approaches; however, the
unique integration of its three components may be espe-
cially effective for addressing emotion dysregulation
among chronic pain patients. To be clear, whether or
not they are combined in an integrative treatment pack-
age like MORE, therapeutic techniques involving mind-
fulness, reappraisal, and savoring can successfully treat
the difficulties in emotion-generation and emotion regu-
lation failures associated with maladaptive pain coping.
Moreover, new affect regulation interventions and those
that have demonstrated success in reducing suicidal
ideation and substance misuse outside the context of
chronic pain might be translated and tailored to address
the unique clinical features of comorbid pain, suicidality,
and opioid misuse.
Conclusion
Cognitive, affective, and physiological antecedents and
consequences of pain render chronic pain patients pre-
scribed long-term opioid pharmacotherapy vulnerable to
opioid misuse and suicidality—two hazardous behaviors
with significant mortality risk. Established bidirectional
relationships between pain, opioid use, and affective dis-
tress underscore the potential role of emotion dysregula-
tion in the development and maintenance of opioid
misuse and suicidality among chronic pain patients. As
such, emotion dysregulation represents an important
transdiagnostic treatment target for future prevention
and intervention approaches designed to reduce lethal
and life-threatening behaviors among opioid-treated
chronic pain patients.
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